Hematol Oncol Stem Cell Ther . 2020 Sep 26;S1658-3876(20)30147-3.
Ioannis A Voutsadakis 1
How many Cancer and Vitamin D meta-analyses will be needed
before there is ANY change by the medical community?
Pages listed in BOTH Breast Cancer AND Meta-analysis
- Deaths from many types of Cancer associated with low vitamin D- review of meta-analyses Sept 2020
- Breast Cancer again associated with low vitamin D – 15th meta-analysis Sept 2020
- Breast Cancer risk reduced 17 percent by 1 hour of daily summer sun – meta-analysis Jan 2020
- Breast Cancer reduced 20 percent by fish (Omega-3) – meta-analysis Feb 2019
- Breast Cancer rate reduced by 40 percent with Omega-3 – meta-analysis June 2013
- Breast Cancer Mortality reduced 60 percent if more than 60 ng of Vitamin D – meta-analysis June 2017
- Increased risk of some female cancers if low vitamin D (due to genes) – meta-analysis June 2015
- Cancer (colon, breast, lymph) survival about 2X better with high level vitamin D – meta-analysis July 2014
- Cancer survival 4 percent more likely with just a little more vitamin D (4 ng) - meta-analysis July 2014
- Death due to breast cancer reduced 40 percent if high vitamin D – meta-analysis April 2014
- More survive Breast Cancer if more vitamin D – 2X fewer deaths with just 30 ng -meta-analysis March 2014
- Colorectal and Breast Cancer – Vitamin D is associated with fewer deaths – meta-analysis Feb 2014
- Breast Cancer – review of 2 RCT did not find association with 1000 IU of Vitamin D – July 2013
- Breast Cancer post menopause down 12 percent for every 5 ng of vitamin D – meta-analysis May 2013
- 3.2 percent less Breast Cancer for 2.4 ng more vitamin D – meta-analysis June 2013
- Breast Cancer survival 2X more likely if vitamin D sufficient – meta-analysis May 2013
- Meta-graphs of vitamin D and Cancer – Dec 2011
- Meta-analysis not find low vitamin D years before breast cancer – Aug 2010
- Meta-analysis confirmed that vitamin D and calcium prevents breast cancer – June 2010
- Meta-analysis found vitamin D association with colon but not prostate nor breast cancer May 2010
- Breast cancer association with low vitamin D suggested by Meta-analysis -April 2010
- Meta-analysis did not find strong association between vitamin D and breast cancer risk -April 2010
- - - - - - - - - - - - - - - - - - - - -
- Colorectal cancer treated by Vitamin D – 19th meta-analysis – Sept 2020
- Breast, Prostate and Colon Cancers are still strongly associated with low Vitamin D – Grant Jan 2020
15 articles are in both Cancer and Meta-analysis categories 8 articles are in both Prostate Cancer and Meta-analysis categories
- Meta-analysis of Vitamin D lists meta-analyses by type of health problem
- - - - - - - - - - - - - - - - - - - - -
Background: Vitamin D is a steroid hormone that exerts its actions through ligation of the vitamin D receptor (VDR), a transcription factor of the nuclear receptor family. VDR has not only physiologic actions in calcium metabolism but also several other cellular effects through extensive binding to the DNA and modification of genome expression. In cancer, it has neoplasia-suppressive effects and various mechanisms of action mediating cancer cell inhibition have been described. Vitamin D deficiency has been linked to increased risk of breast cancer. A role of the vitamin once the disease has been diagnosed is also probable.
Methods: A systematic review and meta-analysis of studies that report on vitamin D levels (in the form of its main circulating metabolite, 25-hydroxyvitamin D [25-OHD]) in patients with newly diagnosed breast cancer was performed. Outcomes of interest included the levels of serum 25-OHD in patients with breast cancer, those of matched controlled, in studies that included controls, as well as respective percentages of patients and controls with deficient and insufficient 25-OHD levels.
Results: A total of 25 studies (10 with controls and 15 without controls) provided data on the outcomes of interest. Populations from all continents, besides Australia, were represented in the studies. The mean level of 25-OHD in patients with breast cancer was 26.88 ng/mL (95% CI 22.8-30.96 ng/mL) and the mean level of 25-OHD in control patients was 31.41 ng/mL (95% CI 19.31-43.5 ng/mL). In the patients with breast cancer group, 45.28% (95% CI 24.37%-53.51%) had levels of 25-OHD below 20 ng/mL, whereas this percentage was 33.71% (95% CI 21.61%-45.82%) in controls.
Similarly, 67.44% (95% CI 48.32%-86.55%) of patients with breast cancer had a baseline level of 25-OHD below 30 ng/mL, whereas this percentage was 33.71% (95% CI 21.61%-45.82%) in controls.
Conclusion: A high prevalence of vitamin D insufficiency is observed in patients with newly diagnosed breast cancer and may be linked pathophysiologically with breast cancer development or progression. Therapeutic benefits may be provided by manipulation of the vitamin D pathway in breast cancer.Breast Cancer again associated with low vitamin D – 15th meta-analysis Sept 2020
414 visitors, last modified 02 Oct, 2020,